Daniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.08, for a total value of $80,800.00. Following the completion of the sale, the chief financial officer now owns 35,190 shares of the company’s stock, valued at $284,335.20. The trade was a 22.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Zynex Stock Performance

Shares of Zynex stock opened at $8.01 on Thursday. The company has a market capitalization of $255.12 million, a PE ratio of 53.40 and a beta of 0.49. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a 50-day simple moving average of $8.25 and a two-hundred day simple moving average of $8.62. Zynex, Inc. has a one year low of $7.15 and a one year high of $13.77.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same period in the previous year, the company posted $0.10 earnings per share. The firm’s revenue was up .1% on a year-over-year basis. Research analysts expect that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. HC Wainwright lifted their price objective on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada decreased their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Institutional Investors Weigh In On Zynex

Large investors have recently modified their holdings of the business. Gladius Capital Management LP grew its stake in shares of Zynex by 53.4% during the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after acquiring an additional 1,742 shares during the last quarter. Investment Partners Asset Management Inc. purchased a new stake in shares of Zynex during the third quarter worth about $96,000. Hsbc Holdings PLC purchased a new stake in shares of Zynex during the second quarter worth about $113,000. Quest Partners LLC grew its stake in shares of Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after acquiring an additional 11,195 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock valued at $182,000 after buying an additional 1,846 shares during the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.